Friday, July 17, 2015
EMD Serono, the U.S. biopharmaceutical business of Germany’s Merck, has announced two critical management appointments to lead its entry into oncology. EMD Serono’s diversified oncology and immuno-oncology pipeline includes multiple, high-priority projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient need.
Accenture, a global management consulting, technology services and outsourcing company, has expanded the Accenture Life Sciences Cloud for R&D, powered by Oracle, with the addition of enhanced clinical data management capabilities. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market.
Eisai Inc., a U.S. subsidiary of Eisai Co., a global R&D-based pharmaceutical company headquartered in Japan, plans to restructure its operations in the U.S., including a reduction of its workforce by approximately 25% across various U.S. functions. This realignment supports Eisai’s desire to create a more efficient and focused organization.
Eisai and Merck, through a subsidiary, have formed a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck’s anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name Keytruda), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. under the brand name Lenvima, lenvatinib) and eribulin mesylate (a microtubule dynamics inhibitor marketed in nearly 60 countries including Japan, the U.S. and Europe under the brand name Halaven, eribulin) in multiple clinical trials.
Lexicon Pharmaceuticals has announced management additions directed toward the completion of phase III development and commercial preparations for telotristat etiprate in carcinoid syndrome and preparation for phase III initiation and commercial readiness for sotagliflozin (LX4211) in type 1 diabetes.
Accenture, an Ireland-based global management consulting, technology services and outsourcing company, has launched Accenture Life Sciences Cloud for R&D, which speeds clinical development, helps improve patient outcomes and creates greater R&D efficiency through a new single analytics platform that brings together multiple internal and external data sources across clinical, safety, regulatory and operational functions.
The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.
Eisai and Helsinn Group have announced the FDA approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged one month to less than 17 years.
The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership bringing Japanese experience and investment to the global fight against infectious diseases, has announced three grants worth a total of $6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.